Retinal Vein Occlusion Market Expected to Reach $5.45 Billion by 2034
The market for retinal vein occlusion (RVO) is predicted to witness significant growth from 2025 to 2034, with the global market size expected to reach approximately USD 5.45 billion by 2034, marking an impressive CAGR of 6.81%. Factors such as increased awareness about RVO and the emergence of new treatment options are driving this growth. Moreover, the provision of accessibility audit training for healthcare professionals, especially in rural areas, is aiding in spreading awareness about RVO in developing regions.
North America currently leads the retinal vein occlusion market, holding a dominant market share of 42% in 2024. The region’s advanced healthcare infrastructure and robust regulatory environment contribute to its market leadership. Meanwhile, Asia Pacific is anticipated to witness the fastest growth with a projected CAGR of 8.9% during the forecast period.
In terms of disease types, central retinal vein occlusion (CRVO) accounted for the largest market share of 71% in 2024, while the branch retinal vein occlusion (BRVO) segment is expanding steadily with a projected CAGR of 7.5%. The treatment landscape is also evolving, with anti-vascular endothelial growth factor (Anti-VEGF) therapies capturing 67% of the market share in 2024, and corticosteroid drugs anticipated to grow at a significant CAGR of 5% in the coming years.
Artificial intelligence (AI) integration is playing a crucial role in revolutionizing the diagnosis and management of RVO. AI-powered systems are enhancing disease detection capabilities, providing early diagnosis, and enabling treatment accessibility in remote areas with limited resources. Deep learning algorithms, such as the FDA-cleared IDx-DR system, are proving effective in detecting diabetic retinal vein occlusion, thus reducing disparities in vision loss from diabetes.
Moreover, the integration of AI and digital health tools, including teleophthalmology platforms, is facilitating early disease diagnosis, enhancing treatment accessibility, and improving healthcare outcomes. Healthcare professionals are increasingly relying on AI algorithms to provide accurate data and answers to medical queries, further advancing the field of ophthalmology.
The United States is poised to maintain its market leadership in retinal vein occlusion, with a projected market size of around USD 1.93 billion by 2034, growing at a CAGR of 7.01%. The country’s advanced healthcare infrastructure, regulatory approvals for innovative treatments, and favorable reimbursement policies contribute to its market dominance. Roche’s reintroduction of Susvimo® (ranibizumab injection) underscores the country’s commitment to providing innovative treatment options for RVO patients.
In Asia Pacific, countries like Japan, India, and China are witnessing significant market growth due to the increasing elderly population and the prevalence of RVO among them. India, in particular, is leading the Asian market owing to its well-established healthcare system and government support for patients with eye-related conditions. As the market continues to evolve, the role of AI and innovative technologies will be instrumental in improving RVO diagnosis and treatment outcomes across regions.
